Author: Jesse Landry

SKYX Platforms Corp. does not sell gadgets. It sells gravity. Not the poetic kind, the kind that keeps buildings honest. Founded in 2004, now headquartered in Pompano Beach, Florida, and publicly traded as NASDAQ: SKYX, the company has spent two decades staring at the ceiling and asking a question most of the industry ignored. Why is the most powerful point in the room still treated like dead space? On January 26, 2026, SKYX closed a $25 million registered direct offering priced at $2.50 per share. Ten million shares. No warrants. One institutional investor stepping in clean. Roth Capital Partners ran…

Anthropic just put a $20 billion period at the end of a sentence the market was already afraid to finish reading. Founded in 2021 by seven former OpenAI executives and headquartered at 548 Market Street in San Francisco, Anthropic has been moving like a research lab that accidentally learned how to sell, or maybe a sales machine disciplined enough to believe in consequences. This week, that tension crystallized into a Series G that closed at $20 billion and stamped a $350 billion post-money valuation on the door. The round landed January 27 to January 28, 2026, after investor demand doubled…

On January 28, 2026, a quiet address on Union Avenue in Baltimore put a loud number on the board. CraniUS Therapeutics LLC closed a $20 million Series B, and the timing matters because the problem they are chasing has been winning for decades. The blood brain barrier blocks roughly 95 percent of drugs from reaching brain tissue, which means innovation has been parked outside the venue, listening through the walls, hoping the bass leaks out. CraniUS Therapeutics did not show up with hope. It showed up with hardware. Founded in May 2021 by Dr. Chad Gordon after more than fifteen…

January does not usually whisper. It clears its throat and tells you who is serious. Cellares just did that out loud. South San Francisco based, founded in April 2019, built by Fabian Gerlinghaus, Omar Kurdi, and Alex Pesch, this company did not show up to cell therapy manufacturing to decorate the room. It showed up because the science was ready and the factories were not. Five years later, the gap between discovery and delivery has a name, an address, and a balance sheet that just got heavier. This week Cellares closed a $257 million Series D, led by BlackRock with…

January 28, 2026 lands quietly on the calendar, but nothing about Eliyan Corporation is subtle. Santa Clara born, April 2021 official, 2016 in the lab, this company did not show up to decorate the AI boom. It showed up to deal with the physics. When bandwidth chokes, latency lies, and power budgets tap out, Eliyan steps into the room like it owns the wiring behind the walls. This story starts with Ramin Farjadrad, co-founder and Chief Executive Officer, a Stanford-trained engineer with more than 130 patents and a résumé that reads like a semiconductor speedrun. Velio Communications. Aquantia. Marvell. The…

In 2011, in Warren, New Jersey, a healthcare technologist named Aarti Vaishnav built a piece of software as a favor. Not a pitch deck favor. A real one. A friend running a Physical Therapy program was buried under clinical placements, compliance paperwork, and inbox chaos. Aarti Vaishnav saw the mess, wrote code, and solved a problem that higher education had quietly accepted as normal. That favor became Exxat, and fifteen years later it just pulled a minority growth investment from Accel-KKR without giving up the wheel. On January 22, 2026, Exxat announced the deal. The amount stayed private. The intent…

Elysium Therapeutics is not a name you hear shouted. It is one you hear whispered by people who have spent decades inside pharma boardrooms, regulatory halls, and emergency rooms where time is measured in breaths. Based in Lyons, Colorado and founded in May 2013, the company was built for a problem that does not trend until it kills enough people to force attention. Synthetic opioid overdoses, especially oral fentanyl, are not a policy debate inside Elysium. They are a chemistry problem that refuses to be solved by slogans. Alex Greg Sturmer and Dr. Thomas E. Jenkins have been building companies…

Three years ago, two Princeton seniors walked out of investment banking with a thesis, a chip on their shoulder, and a very specific irritation. Gabriel Stengel and John Willett had seen how much institutional finance still ran on human exhaustion, late nights, and manual work disguised as rigor. New York City became the proving ground. Rogo became the bet. Not a chatbot, not a toy, but an AI platform built to speak fluent finance and survive compliance rooms without flinching. On January 28, 2026, that bet cleared another bar. Rogo raised a $75 million Series C led by Sequoia Capital,…

January 28, 2026 landed with the sound of air brakes and bank wires. Datatruck, the Chicago based freight tech company building an AI native operating system for long haul carriers, closed a $12 million Series A led by Avenue Growth Partners. Not a flashy demo day moment. A working capital moment. The kind that shows up after the product has already been pulling weight in the real world. Datatruck started in 2022 after Shah Rahmanov spent years watching trucking companies bleed money quietly. Paper, spreadsheets, disconnected systems, no real view into profitability. Losses hiding in plain sight. After five months…

Los Angeles restaurants are tired. Not sleepy tired. Platform tired. The kind of tired that comes from paying a 25 percent toll to middlemen who own the guest, own the data, and smile while doing it. Curate Technologies showed up with a quieter flex and a sharper idea. If guests hate downloading another app, stop asking them to. Curate does not chase loyalty. Curate removes the friction that keeps loyalty from ever starting. Founded in February 2021, Curate Technologies sits at the intersection of hospitality and instant software. Two Stanford trained engineers, Grant Russell and Alex Wang, started working on…